Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: In one aspect, inks for use with a three-dimensional printing system are described herein. In some embodiments, an ink described herein comprises up to about 90 wt. % monofunctional curable material, up to about 10 wt. % difunctional curable material, and up to about 10 wt. % liquid rubber, based on the total weight of the ink, wherein the liquid rubber comprises one or more curable moieties. In some cases, the liquid rubber comprises one or more ethyleneically unsaturated moieties. For example, in some instances, the liquid rubber comprises a butadiene acrylonitrile copolymer.

Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: A lightweight throttling mechanism allows for dynamic control of access to resources in a distributed environment. Each request received by a server of a server group is parsed to determine tokens in the request, which are compared with designated rules to determine whether to process or reject the request based on usage data associated with an aspect of the request, the token values, and the rule(s) specified for the request. The receiving of each request can be broadcast to throttling components for each server such that the global state of the system is known to each server. The system then can monitor usage and dynamically throttle requests based on real time data in a distributed environment.

Abstract: The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.

Abstract: The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8, A, X and n are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.

Abstract: The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.

Abstract: In one aspect, inks for use with a three-dimensional printing system are described herein. In some embodiments, an ink described herein comprises up to about 90 wt. % monofunctional curable material, up to about 10 wt. % difunctional curable material, and up to about 10 wt. % liquid rubber, based on the total weight of the ink, wherein the liquid rubber comprises one or more curable moieties. In some cases, the liquid rubber comprises one or more ethyleneically unsaturated moieties. For example, in some instances, the liquid rubber comprises a butadiene acrylonitrile copolymer.

Abstract: A lightweight throttling mechanism allows for dynamic control of access to resources in a distributed environment. Each request received by a server of a server group is parsed to determine tokens in the request, which are compared with designated rules to determine whether to process or reject the request based on usage data associated with an aspect of the request, the token values, and the rule(s) specified for the request. The receiving of each request can be broadcast to throttling components for each server such that the global state of the system is known to each server. The system then can monitor usage and dynamically throttle requests based on real time data in a distributed environment.

Abstract: The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8, A, X and n are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.

Abstract: A method and device for real-time mechanical and dosimetric quality assurance measurements in radiation therapy provides a unified measurement of mechanical motion and radiation components of the machine. The device includes an imaging surface for receiving multiple energy sources. The imaging surface has an imaging plane positioned on a same plane as an isocenter of a medical accelerator. A camera measures and records data related to the multiple energy sources. A mirror system can be used to direct the multiple energy sources to the camera for further processing. However, in some instances the mirror system may not be necessary. The device can also include computer control in order to automate the movement of the device and/or automation of the QA protocol. The device can also be used in executing a method for assessing gantry and collimator rotation.

Abstract: A method and device for real-time mechanical and dosimetric quality assurance measurements in radiation therapy provides a unified measurement of mechanical motion and radiation components of the machine. The device includes an imaging surface for receiving multiple energy sources. The imaging surface has an imaging plane positioned on a same plane as an isocenter of a medical accelerator. A camera measures and records data related to the multiple energy sources. A mirror system can be used to direct the multiple energy sources to the camera for further processing. However, in some instances the mirror system may not be necessary. Accordingly, a single device can be used to unify the measurement of mechanical motion and radiation component of the machine. The device can also include computer control in order to automate the movement of the device and/or automation of the QA protocol.

Abstract: The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.

Abstract: The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis and cancer.

Abstract: A method and device for real-time mechanical and dosimetric quality assurance measurements in radiation therapy provides a unified measurement of mechanical motion and radiation components of the machine. The device includes an imaging surface for receiving multiple energy sources. The imaging surface has an imaging plane positioned on a same plane as an isocenter of a medical accelerator. A camera measures and records data related to the multiple energy sources. A mirror system can be used to direct the multiple energy sources to the camera for further processing. However, in some instances the mirror system may not be necessary. The device can also include computer control in order to automate the movement of the device and/or automation of the QA protocol. The device can also be used in executing a method for assessing gantry and collimator rotation.

Abstract: A lightweight throttling mechanism allows for dynamic control of access to resources in a distributed environment. Each request received by a server of a server group is parsed to determine tokens in the request, which are compared with designated rules to determine whether to process or reject the request based on usage data associated with an aspect of the request, the token values, and the rule(s) specified for the request. The receiving of each request can be broadcast to throttling components for each server such that the global state of the system is known to each server. The system then can monitor usage and dynamically throttle requests based on real time data in a distributed environment.

Abstract: A method and device for real-time mechanical and dosimetric quality assurance measurements in radiation therapy provides a unified measurement of mechanical motion and radiation components of the machine. The device includes an imaging surface for receiving multiple energy sources. The imaging surface has an imaging plane positioned on a same plane as an isocenter of a medical accelerator. A camera measures and records data related to the multiple energy sources. A mirror system can be used to direct the multiple energy sources to the camera for further processing. However, in some instances the mirror system may not be necessary. Accordingly, a single device can be used to unify the measurement of mechanical motion and radiation component of the machine. The device can also include computer control in order to automate the movement of the device and/or automation of the QA protocol.

Abstract: The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis and cancer.